Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Cell Therapy
Stem Cell Therapy For Pets – Laleigh Before
Posted: March 25, 2013 at 8:44 am
Stem Cell Therapy For Pets - Laleigh Before After
By: NewmanVets
Posted in Cell Therapy
Comments Off on Stem Cell Therapy For Pets – Laleigh Before
Stem Cell Therapy For Pets – Sammy Before
Posted: March 25, 2013 at 8:44 am
Stem Cell Therapy For Pets - Sammy Before After
Amazing before and after footage of Sammy, a yellow lab who received stem cell therapy for his arthritic joints. For more information about stem cell therapy...
By: NewmanVets
More here:
Stem Cell Therapy For Pets - Sammy Before
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Stem Cell Therapy For Pets – Sammy Before
Stem Cell Therapy Cures Paralyzed Vet – Video
Posted: March 25, 2013 at 8:44 am
Stem Cell Therapy Cures Paralyzed Vet
By: TheVideOHM
Follow this link:
Stem Cell Therapy Cures Paralyzed Vet - Video
Posted in Cell Therapy
Comments Off on Stem Cell Therapy Cures Paralyzed Vet – Video
Watch Stem Cell Therapy Cures Paralyzed Vet Video – Video
Posted: March 25, 2013 at 8:44 am
Watch Stem Cell Therapy Cures Paralyzed Vet Video
By: Shah Ali
See the original post:
Watch Stem Cell Therapy Cures Paralyzed Vet Video - Video
Posted in Cell Therapy
Comments Off on Watch Stem Cell Therapy Cures Paralyzed Vet Video – Video
Cell Therapy Shows Promise For Advanced Leukemia In Adults
Posted: March 23, 2013 at 11:45 pm
Editor's Choice Academic Journal Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Stem Cell Research Article Date: 21 Mar 2013 - 12:00 PDT
Current ratings for: Cell Therapy Shows Promise For Advanced Leukemia In Adults
3 (1 votes)
1 (1 votes)
Similar immune-system therapy has proven effective in children with this cancer as well as in adults with a similar type of leukemia, however, this is the first time this specific therapy has worked in adults.
The findings of the current study were based on five patients with acute lymphoblastic leukemia (ALL). T cells were extracted from the patient and modified to express a receptor for protein on other immune cells - called B cells - that are found in both cancerous and healthy tissues.
ALL is a cancer of the blood and bone marrow which progresses quickly - if left untreated, patients sometimes die within weeks. The first treatment is generally three phases of chemotherapy drugs.
For most patients, this puts the cancer in remission. However, it often comes back. The second treatment agenda is usually another round of chemotherapy followed by a bone marrow transplant.
The authors point out that when the cancer returns, it is often immune to many chemotherapy drugs. Therefore, Dr. Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City, and his colleagues set out to test a different approach.
The five participating patients received infusions of their altered T cells after undergoing standard chemotherapy. All five patients saw a total remission - for one patient this occured within just eight days, according to the researchers.
Go here to see the original:
Cell Therapy Shows Promise For Advanced Leukemia In Adults
Posted in Cell Therapy
Comments Off on Cell Therapy Shows Promise For Advanced Leukemia In Adults
Cell Therapy For Aggressive Leukemia Uses Patient’s Own T Cells, Has Very Promising Results
Posted: March 23, 2013 at 11:45 pm
Leukemia is never an easy disease to beat back, but adults with relapsed B cell acute lymphoblastic leukemia, or B-ALL, have especially grim prospects. This particular kind of blood cancer progresses quickly, and has only a 30 to 40 percent cure rate in adults. Chemotherapy drugs can sometimes clear out the cancer the first time around, but some patients relapse, requiring another round of chemotherapy, then a bone marrow transplant. But this second round can sometimes fail because the recurring leukemia proves resistant to the drugs.
Now, in a paper published Wednesday in the journal Science Translational Medicine, scientists have successfully treated B-ALL patients by inserting new genetic material into some of their T cells. The cell therapy allows the patients immune system to find and destroy the places where the blood cancer is hiding out.
In one case, the treatment cleared up a patients leukemia in a little more than a week.
We had hoped, but couldnt have predicted that the response would be so profound and rapid, Memorial Sloan-Kettering Cancer Center researcher Renier J. Brentjens told the New York Times.
Brentjens and his colleagues treated five B-ALL patients with some of their own T cells, which were genetically programmed to recognize a particular protein on the surface of B cells, the immune system cells that are affected by this kind of leukemia. The reengineered T cells then lay waste to all of the patients B cells, healthy and cancerous alike (the loss of healthy B cells can be treated later).
Were creating living drugs, senior author Michel Sadelain told the New York Times. Its an exciting story thats just beginning.
Still, the treatment is far from 100 percent perfect. Three of the five patients in the study have been in remission for anywhere between five months and two years. Another patient died of a blood clot after going in to remission, and another relapsed again possibly because a steroid treatment meant to control a side effect of the cell therapy may have wiped out the souped-up T cells before they could attack the B cells. The three survivors may yet relapse again.
And there are risks associated with the cell therapy. The T cells offensive onslaught can create whats called a cytokine storm, a potentially fatal immune chain reaction that usually induces an extremely high fever.
"This is very early in development," University of Pennsylvania researcher David Porter, who was not involved with the study, told US News & World Report. "We are just starting to learn about the short-term side effects, and we don't know about the long-term effectiveness or safety."
At the moment, this kind of cell therapy is being used as a lead-in to a bone marrow transplant. But in the future, doctors may be able to just use immunotherapy by itself.
Continue reading here:
Cell Therapy For Aggressive Leukemia Uses Patient's Own T Cells, Has Very Promising Results
Posted in Cell Therapy
Comments Off on Cell Therapy For Aggressive Leukemia Uses Patient’s Own T Cells, Has Very Promising Results
Stem Cell Therapy For Pets – Kye Before
Posted: March 23, 2013 at 4:43 pm
Stem Cell Therapy For Pets - Kye Before After
Amazing before and after footage of Kye, an 11 year old lab who received stem cell therapy for his arthritis. For more information about stem cell therapy fo...
By: NewmanVets
Continued here:
Stem Cell Therapy For Pets - Kye Before
Posted in Cell Therapy
Comments Off on Stem Cell Therapy For Pets – Kye Before
Naples seminar to look at stem cell therapy to aid macular degeneration
Posted: March 23, 2013 at 4:43 pm
Retina Consultants of Southwest Florida
Dr. Ashish Sharma of Retina Consultants of Southwest Florida conducts an eye exam.
The Naples seminar will be from 1 p.m. to 4 p.m. at the Hilton Naples, 5111 U.S. 41 North.
An identical seminar in Fort Myers will be Monday from 9 a.m. to noon at Harborside Convention Center, 1375 Monroe St.
To register to attend, call 1-866-946-6824, or go to http://www.MassEyeAndEar.organization/symposium.
NAPLES Leonard Klein plays tennis and bridge, and both of his games could improve if he has stem cell therapy some day.
The 80-year-old suffers from dry macular degeneration. While his vision loss hasnt worsened in recent months, theres no telling the future.
Studies are under way to see if stem cell therapy can reverse vision loss for people suffering from age-related macular degeneration.
Klein will sign up if such a study opens up to Southwest Florida.
Im a risk taker and always have been, he said recently, before heading to a bridge game in the care center at the Vi at Bentley Village, a continuing care retirement community in North Naples.
See the original post here:
Naples seminar to look at stem cell therapy to aid macular degeneration
Posted in Cell Therapy
Comments Off on Naples seminar to look at stem cell therapy to aid macular degeneration
DOH restricts hospitals amid stem- cell therapy craze
Posted: March 20, 2013 at 4:42 pm
The Department of Health (DOH) has restricted hospitals and other facilities from using genetically-altered cells and tissues of human in carrying out stem-cell therapy and treatments in the country. Health secretary Enrique Ona added that their department also prohibits the use of umbilical cord, fat-derived human stem cells, and live animal stem cells for the conduct of the procedure locally. On Wednesday, DOH released Administrative Order (AO) 2013-0012 which seeks to ensure the safety of people who want to undergo human stem cell and cell-based therapies.
The AO also prohibits for human treatment and research the creation of human embryos and their derivatives, the use of aborted human fetal stem cells and their derivatives, and plant parts labeled as stem cells, the order stated. Ona hopes AO will make effective and ethical stem cell modalities and practices that will be at par with emerging international and global standards on the very complex nature of this therapy. He explained the AO also hopes to prevent the introduction, transmission, and spread of communicable diseases by ensuring a minimum quality of service and staff qualification rendered by hospitals and other health facilities capable of utilizing human stem cell preparations and cell-based therapies. These guidelines will classify which stem cell preparations and therapies will be registered and allowed with certain restrictions, Ona said in a statement. Preparations that will be allowed include those with adult human stem cells, human umbilical cord stem cells, and human organ-specific cells, he noted. He explained that health facilities utilizing stem cell preparations and cell-based or cellular therapies will be mandated to comply with the guidelines set by DOHs Bioethics Advisory Board. The Borad, Ona notes, will ensure that ethical and professional standards are upheld and that contentious scientific, ethical and legal issues are addressed. He said charges and complaints shall be addressed to the DOH Bureau of Health Facilities & Services and the Philippine Food and Drug Agency. Stem cell therapy and treatments are medical procedures where doctors replace malignant cells with healthier cells in an effort to cure or address ailments like cancer. Some facilities also use the procedure for cosmetic purposes, targeting components of the skin like collagen to make patients look younger and healthy.
Read the rest here:
DOH restricts hospitals amid stem- cell therapy craze
Posted in Cell Therapy
Comments Off on DOH restricts hospitals amid stem- cell therapy craze
NeoStem’s Subsidiary, Progenitor Cell Therapy , Launches Web-Based Service for Real-Time Cell Therapy Product Tracking
Posted: March 18, 2013 at 11:47 pm
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that the Company's contract development and manufacturing ("CDMO") subsidiary, Progenitor Cell Therapy ("PCT"), has launched a new service offering, using a custom developed Internet/Web application to further its position as a technology leader for cell therapy. The new service, an automated software system called "PCTFORME.COM", resides in a highly secure, cloud based computing environment, available 24/7, and serves to enhance PCT's service offering to its growing client base. This service has been launched for a major client and is now available for all of PCT's existing and future stem cell clients.
PCTFORME allows PCT's clients to securely access patient details on-line and provides for real time product ordering, processing and retrieval via automated communications between PCT's clients and laboratory staff. The system is expected to significantly enhance communication by enabling easy tracking of current processing, increasing PCT's efficiencies and streamlining the process for the ordering of patient cells for infusion. PCTFORME is HIPAA compliant and built on a proven Microsoft software platform and supporting cloud based hardware infrastructure.
Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, said, "The need to service the demand, in both volume and variety of procedures, continues to grow as PCT serves our client base. The efficiencies gained in order entry, cell product inventory management, and real time procedure result reporting is expected to improve patient care through enhanced communication, control and transparency. In this regard, PCTFORME represents a patient product management breakthrough in stem cell processing."
"As the field of cell therapy continues to emerge, we believe technology will enable us to reduce costs, better service our clients and build scalable operations to be ready for the future when cell therapy becomes standard of care in medical practice," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "Our management is focused on evaluating, developing and incorporating such technologies into our state-of-the-art contract development and manufacturing business to assist our clients, as well as our clinical development subsidiaries, with their cell therapy product development, and in preparation to launch them into the clinic."
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. http://www.neostem.com
About Progenitor Cell Therapy, LLC ("PCT")
PCT, a wholly owned subsidiary of NeoStem, Inc., is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice ("cGMP") development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. http://www.pctcelltherapy.com
Forward-Looking Statements for NeoStem, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Read the rest here:
NeoStem's Subsidiary, Progenitor Cell Therapy , Launches Web-Based Service for Real-Time Cell Therapy Product Tracking
Posted in Cell Therapy
Comments Off on NeoStem’s Subsidiary, Progenitor Cell Therapy , Launches Web-Based Service for Real-Time Cell Therapy Product Tracking